FDA To Release Warning Letter Responses, Sans Some Related Materials
This article was originally published in The Gray Sheet
Executive Summary
A six-month pilot program to post FDA warning letter responses on the agency's website, at the recipient's request, will elevate the profile of companies seeking to allay compliance concerns
You may also be interested in...
Device Warning Letter Pilot Discontinued; OCC Review Cited As Alternative
The Medical Device Initiative Grassroots Task Force will be briefed regularly on FDA's warning and untitled letter activities, following the agency's decision to end its device center warning letter pilot program
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.